1. Home
  2. SPE vs ATOS Comparison

SPE vs ATOS Comparison

Compare SPE & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPE
  • ATOS
  • Stock Information
  • Founded
  • SPE 1993
  • ATOS 2009
  • Country
  • SPE United States
  • ATOS United States
  • Employees
  • SPE N/A
  • ATOS N/A
  • Industry
  • SPE Finance/Investors Services
  • ATOS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPE Finance
  • ATOS Health Care
  • Exchange
  • SPE Nasdaq
  • ATOS Nasdaq
  • Market Cap
  • SPE 160.8M
  • ATOS 140.9M
  • IPO Year
  • SPE N/A
  • ATOS 2012
  • Fundamental
  • Price
  • SPE $14.62
  • ATOS $0.96
  • Analyst Decision
  • SPE
  • ATOS Strong Buy
  • Analyst Count
  • SPE 0
  • ATOS 3
  • Target Price
  • SPE N/A
  • ATOS $7.00
  • AVG Volume (30 Days)
  • SPE 25.4K
  • ATOS 952.6K
  • Earning Date
  • SPE 01-01-0001
  • ATOS 11-12-2024
  • Dividend Yield
  • SPE 8.55%
  • ATOS N/A
  • EPS Growth
  • SPE N/A
  • ATOS N/A
  • EPS
  • SPE N/A
  • ATOS N/A
  • Revenue
  • SPE N/A
  • ATOS N/A
  • Revenue This Year
  • SPE N/A
  • ATOS N/A
  • Revenue Next Year
  • SPE N/A
  • ATOS N/A
  • P/E Ratio
  • SPE N/A
  • ATOS N/A
  • Revenue Growth
  • SPE N/A
  • ATOS N/A
  • 52 Week Low
  • SPE $10.26
  • ATOS $0.73
  • 52 Week High
  • SPE $12.59
  • ATOS $2.31
  • Technical
  • Relative Strength Index (RSI)
  • SPE 33.49
  • ATOS 24.57
  • Support Level
  • SPE $14.40
  • ATOS $1.17
  • Resistance Level
  • SPE $15.74
  • ATOS $1.30
  • Average True Range (ATR)
  • SPE 0.27
  • ATOS 0.08
  • MACD
  • SPE -0.14
  • ATOS -0.02
  • Stochastic Oscillator
  • SPE 3.73
  • ATOS 1.09

About SPE Special Opportunities Fund Inc

Special Opportunities Fund Inc is the United States based closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds. In addition, it also makes investments in construction materials, consumer finance, healthcare equipment and supplies, independent power and renewable electricity producers, insurance, personal products, professional services and real estate investment trusts.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: